Pleiotropic effects of sitagliptin versus voglibose in patients with type 2 diabetes inadequately controlled via diet and/or a single oral antihyperglycemic agent: A multicenter, randomized trial

BMJ Open Diabetes Research and Care

Volumn 4, Issue 1, 2016, Pages

  Matsushima, Yukiko ^a,b   Takeshita, Yumie ^a,b   Kita, Yuki ^a,b   Otoda, Toshiki ^a,b   Kato, Ken Ichiro ^a,b   Toyama Wakakuri, Hitomi ^a,b   Akahori, Hiroshi ^b   Shimizu, Akiko ^b   Hamaguchi, Erika ^b   Nishimura, Yasuyuki ^b   Kanamori, Takehiro ^a,b   Kaneko, Shuichi ^a   Takamura, Toshinari ^a,b  

^a KANAZAWA UNIVERSITY GRADUATE SCHOOL OF MEDICAL SCIENCE   (Japan)

^b ERA DM Chapter 1 Study Group   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

5,8,11 ICOSATRIENOIC ACID; ACYL COENZYME A DESATURASE; ADIPONECTIN; ALKALINE PHOSPHATASE; CREATININE; CYSTATIN C; DIHOMO GAMMA LINOLENIC ACID; GLUCOSE; HEMOGLOBIN A1C; LINOLEIC ACID; LOW DENSITY LIPOPROTEIN CHOLESTEROL; OLEIC ACID; OMEGA 6 FATTY ACID; PALMITIC ACID; PALMITOLEIC ACID; PROINSULIN; SITAGLIPTIN; STEARIC ACID; URIC ACID; VOGLIBOSE;

ABDOMINAL PAIN; ADULT; ALKALINE PHOSPHATASE BLOOD LEVEL; ARTICLE; CONSTIPATION; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DIARRHEA; DIET; DRUG EFFICACY; FEMALE; FLATULENCE; HEARTBURN; HUMAN; INSULIN RELEASE; LOOSE FECES; MAJOR CLINICAL STUDY; MALE; METEORISM; MULTICENTER STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

EID: 85006212931     PISSN: None     EISSN: 20524897     Source Type: Journal    
DOI: 10.1136/bmjdrc-2015-000190     Document Type: Article

References (41)

1. Ray KK, Seshasai SRK, Wijesuriya S, et al. Effect of intensive control of glucose on cardiovascular outcomes and death in patients with diabetes mellitus: a meta-analysis of randomised controlled trials. Lancet 2009;373:1765-1772.
2. Inzucchi SE, Bergenstal RM, Buse JB, et al. Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care 2012;35:1364-1379.
3. Kirby M, Yu DMT, O’Connor S, et al. Inhibitor selectivity in the clinical application of dipeptidyl peptidase-4 inhibition. Clin Sci (Lond) 2010;118:31-41.
4. Karasik A, Aschner P, Katzeff H, et al. Sitagliptin, a DPP-4 inhibitor for the treatment of patients with type 2 diabetes: a review of recent clinical trials. Curr Med Res Opin 2008;24:489-496.
5. Raz I, Hanefeld M, Xu L, et al. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy in patients with type 2 diabetes mellitus. Diabetologia 2006;49:2564-2571.
6. Iwamoto Y, Taniguchi T, Nonaka K, et al. Dose-ranging efficacy of sitagliptin, a dipeptidyl peptidase-4 inhibitor, in Japanese patients with type 2 diabetes mellitus. Endocr J 2010;57:383-394.
7. Moritoh Y, Takeuchi K, Hazama M. Chronic Administration of Voglibose, an α-Glucosidase Inhibitor, Increases Active Glucagon-Like Peptide-1 Levels by Increasing Its Secretion and Decreasing Dipeptidyl Peptidase-4 Activity in ob/ob Mice. J Pharmacol Exp Ther 2009;329:669-676.
8. Ranganath LMV. Delayed gastric emptying occurs following acarbose administration and is a further mechanism for its anti-hyperglycaemic effect. Diabet Med 1998;15:120-124.
9. [No authors listed]. Report of the expert committee on the diagnosis and classification of diabetes mellitus. Diabetes Care 1997;20:1183-1197.
10. Japanese Society of Nephrology, ed. Clinical practice guidebook for diagnosis and treatment of chronic kidney disease 2012. Tokyo: Tokyo-igakusha, 2012.
11. Horio M. [Development of evaluation of kidney function and classification of chronic kidney disease (CKD)—including CKD clinical practice guide 2012]. Rinsho Byori 2013;61:616-621.
12. Wallace TM, Levy JC, Matthews DR. Use and abuse of HOMA modeling. Diabetes Care 2004;27:1487-1495.
13. Iwata M, Maeda S, Kamura Y, et al. Genetic risk score constructed using 14 susceptibility alleles for type 2 diabetes is associated with the early onset of diabetes and may predict the future requirement of insulin injections among Japanese individuals. Diabetes Care 2012;35:1763-1770.
14. Matthews DR, Hosker JP, Rudenski AS, et al. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985;28:412-419.
15. Yamada Y, Fukuda K, Fujimoto S, et al. SUIT, secretory units of islets in transplantation: an index for therapeutic management of islet transplanted patients and its application to type 2 diabetes. Diabetes Res Clin Pract 2006;74:222-226.
16. Katz A. Quantitative insulin sensitivity check index: a simple, accurate method for assessing insulin sensitivity in humans. J Clin Endocrinol Metab 2000;85:2402-2410.
17. Corpeleijn E, Feskens EJM, Jansen EHJM, et al. Improvements in glucose tolerance and insulin sensitivity after lifestyle intervention are related to changes in serum fatty acid profile and desaturase activities: the SLIM study. Diabetologia 2006;49:2392-2401.
18. Nonaka K, Kakikawa T, Sato A, et al. Efficacy and safety of sitagliptin monotherapy in Japanese patients with type 2 diabetes. Diabetes Res Clin Pract 2008;79:291-298.
19. Iwamoto Y, Tajima N, Kadowaki T, et al. Efficacy and safety of sitagliptin monotherapy compared with voglibose in Japanese patients with type 2 diabetes: a randomized, double-blind trial. Diabetes Obes Metab 2010;12:613-622.
20. Cai X, Han X, Luo Y, et al. Efficacy of dipeptidyl-peptidase-4 inhibitors and impact on β-cell function in Asian and Caucasian type 2 diabetes mellitus patients: a meta-analysis. J Diabetes 2015;7:347-359.
21. Holst JJ, Deacon CF. Glucagon-like peptide 1 and inhibitors of dipeptidyl peptidase IV in the treatment of type 2 diabetes mellitus. Curr Opin Pharmacol 2004;4:589-596.
22. Holst JJ, Gromada J. Role of incretin hormones in the regulation of insulin secretion in diabetic and nondiabetic humans. Am J Physiol Endocrinol Metab 2004;287:E199-E206.
23. Pospisilik JA, Martin J, Doty T, et al. Dipeptidyl peptidase IV inhibitor treatment stimulates beta-cell survival and islet neogenesis in streptozotocin-induced diabetic rats. Diabetes 2003;52:741-750.
24. Gerich J. DPP-4 inhibitors: what may be the clinical differentiators? Diabetes Res Clin Pract 2010;90:131-140.
25. Pratley RE, Schweizer A, Rosenstock J, et al. Robust improvements in fasting and prandial measures of beta-cell function with vildagliptin in drug-naïve patients: analysis of pooled vildagliptin monotherapy database. Diabetes, Obes Metab 2008;10:931-938.
26. Charbonnel B, Karasik A, Liu J, et al. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes inadequately controlled with metformin alone. Diabetes Care 2006;29: 2638-2643.
27. Aso Y, Fukushima M, Sagara M, et al. Sitagliptin, a DPP-4 inhibitor, alters the subsets of circulating CD4+ T cells in patients with type 2 diabetes. Diabetes Res Clin Pract 2015;110:250-256.
28. Kubota A, Maeda H, Kanamori A, et al. Pleiotropic effects of sitagliptin in the treatment of type 2 diabetes mellitus patients. J Clin Med Res 2012;4:309-313.
29. Arjona Ferreira JC, Marre M, Barzilai N, et al. Efficacy and safety of sitagliptin versus glipizide in patients with type 2 diabetes and moderate-to-severe chronic renal insufficiency. Diabetes Care 2013;36:1067-1073.
30. Aschner P, Kipnes MS, Lunceford JK, et al. Effect of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy on glycemic control in patients with type 2 diabetes. Diabetes Care 2006;29:2632-2637.
31. Seo C, Sakamoto M, Nishimura R, et al. Comparison of glycemic variability in patients with type 2 diabetes given sitagliptin or voglibose: a continuous glucose monitoring-based pilot study. Diabetes Technol Ther 2013;15:378-385.
32. Kubota Y, Miyamoto M, Takagi G, et al. The dipeptidyl peptidase-4 inhibitor sitagliptin improves vascular endothelial function in type 2 diabetes. J Korean Med Sci 2012;27:1364-1370.
33. Fujitaka K, Otani H, Jo F, et al. Comparison of metabolic profile and adiponectin level with pioglitazone versus voglibose in patients with type-2 diabetes mellitus associated with metabolic syndrome. Endocr J 2011;58:425-432.
34. Fisman EZ, Tenenbaum A. Adiponectin: a manifold therapeutic target for metabolic syndrome, diabetes, and coronary disease? Cardiovasc Diabetol 2014;13:103.
35. Senmaru T, Fukui M, Kobayashi K, et al. Dipeptidyl-peptidase IV inhibitor is effective in patients with type 2 diabetes with high serum eicosapentaenoic acid concentrations. J Diabetes Investig 2012;3:498-502.
36. Inoue I, Shinoda Y, Nakano T, et al. Acarbose ameliorates atherogenecity of low-density lipoprotein in patients with impaired glucose tolerance. Metab Clin Exp 2006;55:946-952.
37. Vessby B, Gustafsson I-B, Tengblad S, et al. Desaturation and elongation of Fatty acids and insulin action. Ann N Y Acad Sci 2002;967:183-195.
38. Warensjö E, Rosell M, Hellenius M-L, et al. Associations between estimated fatty acid desaturase activities in serum lipids and adipose tissue in humans: links to obesity and insulin resistance. Lipids Health Dis 2009;8:37.
39. Kröger J, Schulze MB. Recent insights into the relation of Δ5 desaturase and Δ6 desaturase activity to the development of type 2 diabetes. Curr Opin Lipidol 2012;23:4-10.
40. Mayneris-Perxachs J, Guerendiain M, Castellote AI, et al. Plasma fatty acid composition, estimated desaturase activities, and their relation with the metabolic syndrome in a population at high risk of cardiovascular disease. Clin Nutr 2014;33:90-97.
41. Lu Y, Vaarhorst A, Merry AHH, et al. Markers of endogenous desaturase activity and risk of coronary heart disease in the CAREMA cohort study. PLoS ONE 2012;7:e41681.